Twice daily ceftriaxone therapy for serious bacterial infections in children

Tasnee Chonmaitree, Blaise L. Congeni, Jose Munoz, Tamara A. Rakusan, Keith R. Powell, Quellin T. Box

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The clinical efficacy and safety of ceftriaxone, a long half-life cephalosporin were evaluated in 48 children with a variety of serious bacterial infections. Clinical cure was achieved in 92% (44 of 48) of patients. Peak serum bactericidal titres for Haemophilus influenzae type b, Streptococcus pneumoniae, Str. pyogenes and Escherichia coli were ≧ 1 :1024. Mean peak and trough ceftriaxone levels were 173 and 42 mg/1, respectively. Mild and transient diarrhoea was observed in 10% of patients. Laboratory side effects encountered were eosinophilia, thrombocytosis and neutropenia in another 8%. Ceftriaxone is a useful antibiotic for common childhood infections. Its prolonged half-life allows twice daily administration which reduces problems related to intravenous therapy as well as the cost and personnel time.

Original languageEnglish (US)
Pages (from-to)511-516
Number of pages6
JournalJournal of Antimicrobial Chemotherapy
Volume13
Issue number5
DOIs
StatePublished - May 1984

Fingerprint

Ceftriaxone
Antibiotics
Bacterial Infections
Escherichia coli
Therapy
Infection
Personnel
Half-Life
Influenza
Escherichia Coli
Efficacy
Costs
Thrombocytosis
Haemophilus influenzae type b
Safety
Eosinophilia
Cephalosporins
Streptococcus pneumoniae
Neutropenia
Diarrhea

ASJC Scopus subject areas

  • Statistics, Probability and Uncertainty
  • Applied Mathematics
  • Physiology (medical)
  • Infectious Diseases
  • Pharmacology (medical)
  • Pharmacology
  • Microbiology

Cite this

Chonmaitree, T., Congeni, B. L., Munoz, J., Rakusan, T. A., Powell, K. R., & Box, Q. T. (1984). Twice daily ceftriaxone therapy for serious bacterial infections in children. Journal of Antimicrobial Chemotherapy, 13(5), 511-516. https://doi.org/10.1093/jac/13.5.511

Twice daily ceftriaxone therapy for serious bacterial infections in children. / Chonmaitree, Tasnee; Congeni, Blaise L.; Munoz, Jose; Rakusan, Tamara A.; Powell, Keith R.; Box, Quellin T.

In: Journal of Antimicrobial Chemotherapy, Vol. 13, No. 5, 05.1984, p. 511-516.

Research output: Contribution to journalArticle

Chonmaitree, T, Congeni, BL, Munoz, J, Rakusan, TA, Powell, KR & Box, QT 1984, 'Twice daily ceftriaxone therapy for serious bacterial infections in children', Journal of Antimicrobial Chemotherapy, vol. 13, no. 5, pp. 511-516. https://doi.org/10.1093/jac/13.5.511
Chonmaitree, Tasnee ; Congeni, Blaise L. ; Munoz, Jose ; Rakusan, Tamara A. ; Powell, Keith R. ; Box, Quellin T. / Twice daily ceftriaxone therapy for serious bacterial infections in children. In: Journal of Antimicrobial Chemotherapy. 1984 ; Vol. 13, No. 5. pp. 511-516.
@article{e02edc14de4f4912808ce89953d5205a,
title = "Twice daily ceftriaxone therapy for serious bacterial infections in children",
abstract = "The clinical efficacy and safety of ceftriaxone, a long half-life cephalosporin were evaluated in 48 children with a variety of serious bacterial infections. Clinical cure was achieved in 92{\%} (44 of 48) of patients. Peak serum bactericidal titres for Haemophilus influenzae type b, Streptococcus pneumoniae, Str. pyogenes and Escherichia coli were ≧ 1 :1024. Mean peak and trough ceftriaxone levels were 173 and 42 mg/1, respectively. Mild and transient diarrhoea was observed in 10{\%} of patients. Laboratory side effects encountered were eosinophilia, thrombocytosis and neutropenia in another 8{\%}. Ceftriaxone is a useful antibiotic for common childhood infections. Its prolonged half-life allows twice daily administration which reduces problems related to intravenous therapy as well as the cost and personnel time.",
author = "Tasnee Chonmaitree and Congeni, {Blaise L.} and Jose Munoz and Rakusan, {Tamara A.} and Powell, {Keith R.} and Box, {Quellin T.}",
year = "1984",
month = "5",
doi = "10.1093/jac/13.5.511",
language = "English (US)",
volume = "13",
pages = "511--516",
journal = "Journal of Antimicrobial Chemotherapy",
issn = "0305-7453",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Twice daily ceftriaxone therapy for serious bacterial infections in children

AU - Chonmaitree, Tasnee

AU - Congeni, Blaise L.

AU - Munoz, Jose

AU - Rakusan, Tamara A.

AU - Powell, Keith R.

AU - Box, Quellin T.

PY - 1984/5

Y1 - 1984/5

N2 - The clinical efficacy and safety of ceftriaxone, a long half-life cephalosporin were evaluated in 48 children with a variety of serious bacterial infections. Clinical cure was achieved in 92% (44 of 48) of patients. Peak serum bactericidal titres for Haemophilus influenzae type b, Streptococcus pneumoniae, Str. pyogenes and Escherichia coli were ≧ 1 :1024. Mean peak and trough ceftriaxone levels were 173 and 42 mg/1, respectively. Mild and transient diarrhoea was observed in 10% of patients. Laboratory side effects encountered were eosinophilia, thrombocytosis and neutropenia in another 8%. Ceftriaxone is a useful antibiotic for common childhood infections. Its prolonged half-life allows twice daily administration which reduces problems related to intravenous therapy as well as the cost and personnel time.

AB - The clinical efficacy and safety of ceftriaxone, a long half-life cephalosporin were evaluated in 48 children with a variety of serious bacterial infections. Clinical cure was achieved in 92% (44 of 48) of patients. Peak serum bactericidal titres for Haemophilus influenzae type b, Streptococcus pneumoniae, Str. pyogenes and Escherichia coli were ≧ 1 :1024. Mean peak and trough ceftriaxone levels were 173 and 42 mg/1, respectively. Mild and transient diarrhoea was observed in 10% of patients. Laboratory side effects encountered were eosinophilia, thrombocytosis and neutropenia in another 8%. Ceftriaxone is a useful antibiotic for common childhood infections. Its prolonged half-life allows twice daily administration which reduces problems related to intravenous therapy as well as the cost and personnel time.

UR - http://www.scopus.com/inward/record.url?scp=0021733435&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021733435&partnerID=8YFLogxK

U2 - 10.1093/jac/13.5.511

DO - 10.1093/jac/13.5.511

M3 - Article

C2 - 6330022

AN - SCOPUS:0021733435

VL - 13

SP - 511

EP - 516

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

SN - 0305-7453

IS - 5

ER -